Statins and the Risk of Colorectal Cancer

Pynter, J.N.; Gruber, Sven; Higgins, Patrick D.

doi:10.1016/j.accreview.2005.08.195

Cited by 43 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, safety of this class of agents was confirmed by several meta-analyses [14,15]. Notwithstanding, several epidemiological studies have suggested that HMG-CoA reductase inhibitors may, in fact, prevent certain solid malignancies such as melanoma, breast, colon, and prostate cancers [16][17][18][19][20]. Likewise, it has been suggested that chronic statin use is linked with a trend toward a lower cancerrelated mortality rate [21].…”

Section: Epidemiological Evidencementioning

confidence: 89%

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Bockorny

Dasanu

2014

Ann Hematol

View full text Add to dashboard Cite

Statins have been shown to possess properties that go beyond their lipid-lowering effects. These agents act on the mevalonate pathway and inhibit synthesis of cholesterol, geranylgeranyl pyrophosphate, and farnesyl pyrophosphate, which are necessary for posttranslational modification of the Rho, Rac, and Ras superfamily of proteins. Early phase studies have demonstrated that this modulation of cellular signaling can ultimately exert pro-apoptotic, anti-angiogenic, and immunomodulatory effects, and might even restore chemosensitivity in several hematologic cancers. Nonetheless, these promising preclinical results have not yet migrated from the bench to the bedside as their effectiveness as adjuvant agents in hematologic malignancies is currently uncertain. In the present review, we summarize the existing evidence stemming from preclinical and clinical studies pertaining to the use of statins as adjuvant therapies in hematologic malignancies, and discuss the new insights gained from the ongoing translational research.

show abstract

Section: Epidemiological Evidencementioning

confidence: 89%

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Bockorny

Dasanu

2014

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…Because more patients will be diagnosed at earlier stage, survival should also improve. Innovative treatments [7] may also improve survival in the future. Thus, improvements in cancer control strategies may differentially affect prevalence, with decreased incidence leading to decreased prevalence, and increased survival leading to increased prevalence.…”

Section: Discussionmentioning

confidence: 99%

“…These increases are likely to continue based on expected trends of an aging and growing population. As public and research attention is increasingly focused on understanding the implications of current and future cancer control strategies, including risk reduction strategies such as continuous use of aspirin and use of non-steroidal anti-inflammatory drugs [4], novel screening technologies such as virtual colonoscopy [5], and innovative treatments [6,7], projections of cancer prevalence are increasingly important for the purposes of resource allocation, and for planning facilities and manpower requirements for cancer treatment. Several studies have reported current cancer prevalence by phase of care [1,8] or lifetime costs of colorectal cancer [1,9], but these approaches only provide prevalence in a single year, and do not allow for projections of cancer prevalence that reflect expected population trends, or change in cancer control strategies.…”

Section: Introductionmentioning

confidence: 99%

Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020

Mariotto

Yabroff

Feuer

et al. 2006

Cancer Causes Control

View full text Add to dashboard Cite

Under assumptions of current cancer control strategies we project that colorectal cancer prevalence will increase more rapidly than the US population, largely due to the aging of the US population. This suggests that considerable resources will be needed in the future for initial, continuing and last year of life treatment of colorectal cancer patients unless notable breakthroughs in primary prevention occur in the future years.

show abstract

“…So reduzieren Ketanest, Thiopental und volatile Anästhetika die Aktivität von natürlichen Killerzellen, T-Lymphozyten und neutrophilen Monozyten [7,8,25,43,51,53,59]. Antikörperpro-duktion, Phagozytoseaktivität, lymphozytäre Proliferation und Cytokinsekretion wiederum werden durch Opioide re- [11] unter zusätzlicher Epiduralanäs-thesie bei Patienten nach radikaler Prostatektomie eine verbesserte Analgesie direkt postoperativ sowie eine signifikant reduzierte Krankenhausverweildauer, jedoch auch einen intraoperativ erhöhten Flüs-sigkeits-und Vasopressorbedarf.…”

Section: Periduralanästhesie Bei Urologischen Eingriffenergebnisqualitätunclassified

Aktuelle anästhesiologische Aspekte bei urologischen Patienten

Groll

2010

Urologe

View full text Add to dashboard Cite

Patients with coronary stents should take clopidogrel and acetylsalicylic acid for 4 weeks or 12 months after stenting. Stopping this medication early, e.g., for surgery, results in a 90-fold increase in the patient's risk for myocardial infarction from stent thrombosis. The mortality due to perioperative acute coronary syndrome clearly exceeds that due to perioperative bleeding complications. If oral medication resulting in platelet inhibition has to be paused "bridging" with short-acting, intravenous GPIIb/IIIa antagonists is possible. In recent years perioperative beta-blockade has been recommended for patients with high coronary vascular risk, and recently also for those with medium or low risk. Current studies, however, indicate that patients on beta-blockers have increased perioperative mortality because of bradycardia, hypotension, and anemia. Therefore, anemia and hypotension should be rigorously avoided.Anesthetic management may have an influence on the postoperative course of cancer. Combined epidural-general anesthesia provides a benefit by minimizing the use of systemic opioids and volatile anesthetics. Presumably, this and a decreased response to surgical stress increase the ability of the patient's immune system to deal with cancer dissemination and micrometastasis.

show abstract

Statins and the Risk of Colorectal Cancer

Cited by 43 publications

References 0 publications

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020

Aktuelle anästhesiologische Aspekte bei urologischen Patienten

Contact Info

Product

Resources

About